Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group

J Nomdedéu; M Hoyos; M Carricondo; J Esteve; E Bussaglia; C Estivill; JM Ribera; R Duarte; O Salamero; D Gallardo; C Pedro; A Aventin; S Brunet; J. Sierra

doi:10.1016/j.leukres.2012.03.019

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group

J Nomdedéu, M Hoyos, M Carricondo, J Esteve, E Bussaglia, C Estivill, JM Ribera, R Duarte, O Salamero, D Gallardo, C Pedro, A Aventin, S Brunet, J. Sierra

Research output: Contribution to journal › Article › Research

33 Citations (Scopus)

Original language	English
Pages (from-to)	990-997
Journal	Leuk Res
Volume	36
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2012.03.019
Publication status	Published - 1 Aug 2012

Access to Document

10.1016/j.leukres.2012.03.019

Cite this

@article{3ea9c1673190416dade72ab172f5d17d,

title = "Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group",

author = "J Nomded{\'e}u and M Hoyos and M Carricondo and J Esteve and E Bussaglia and C Estivill and JM Ribera and R Duarte and O Salamero and D Gallardo and C Pedro and A Aventin and S Brunet and J. Sierra",

year = "2012",

month = aug,

day = "1",

doi = "10.1016/j.leukres.2012.03.019",

language = "English",

volume = "36",

pages = "990--997",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group

AU - Nomdedéu, J

AU - Hoyos, M

AU - Carricondo, M

AU - Esteve, J

AU - Bussaglia, E

AU - Estivill, C

AU - Ribera, JM

AU - Duarte, R

AU - Salamero, O

AU - Gallardo, D

AU - Pedro, C

AU - Aventin, A

AU - Brunet, S

AU - Sierra, J.

PY - 2012/8/1

Y1 - 2012/8/1

U2 - 10.1016/j.leukres.2012.03.019

DO - 10.1016/j.leukres.2012.03.019

M3 - Article

SN - 0145-2126

VL - 36

SP - 990

EP - 997

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -